Prevail
Eli Lilly scoops up gene therapy specialist Prevail Therapeutics for a potential $1.04bn
December 16, 2020Research and Development, Sales and Marketing Eli Lilly, Prevail, acquisition
Eli Lilly has struck a deal to acquire Prevail Therapeutics in a transaction that could be valued at up to …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
